SMARCA4 and lung carcinoma: The demonstration of a synergistic combination effect of KD025 with OXPHOS inhibitors in OXPHOS-sensitive SMARCA4-mutant lung cancer cells is highly promising and could enable expansion of the therapeutic indications for inhibitors of ROCK and OXPHOS.